Vivani Medical, Inc.

Vivani Medical, Inc. is a U.S.-based biopharmaceutical company focused on miniature, ultra long-acting drug implant programs and related delivery platforms. The company also holds neuromodulation assets through its subsidiary Cortigent, which was formed from legacy Second Sight Medical Products and is being positioned as a separate business.

2.71

2.71

— Vivani Medical, Inc.
%
Drug implant programs70% Preclinical and clinical-stage miniature implants designed to deliver GLP-1 therapies over long durations.
Metabolic disease candidates20% Implant-based therapies aimed at obesity, overweight, and type 2 diabetes indications.
Neurostimulation systems10% Brain implant and neuromodulation assets intended to help patients recover critical body functions.

Vivani does not sell commercial products broadly today; its direct counterparties are primarily clinical investigators,...

  • Clinical development partnersprimary

    CROs, trial sites, and manufacturers that support preclinical and clinical testing of implant candidates.

  • Metabolic disease patientsprimary

    People with obesity, overweight, or type 2 diabetes who are the intended users of GLP-1 implant therapies.

  • Neuromodulation patientssecondary

    Patients with severe neurological conditions who may benefit from Cortigent's implantable systems.

  • Regulatory stakeholdersprimary

    FDA and other regulators that determine whether programs can advance into and through clinical development.

Vivani is headquartered in the United States and operates as a development-stage company with U.S...

  • •United States is the main corporate and regulatory base
  • •Clinical and development work is centered on U.S. programs
  • •Australia supports studies of product candidates
  • •Geography matters because trial location affects approvals and timelines
  • •No country revenue disclosure is provided in the excerpts

Vivani's strategy centers on advancing its miniature drug implant platform, with NPM-115, NPM-119, and NPM-139...

01
Advance lead metabolic implant programsshort-term

Clinical progress is the main value driver for a development-stage company.

02
Separate Cortigent into a standalone companyshort-term

A spin-off can create two more focused businesses with distinct capital needs and strategies.

03
Build a broader long-acting implant portfoliomedium-term

A platform approach can extend the technology beyond a single lead asset.

Vivani faces the typical risks of a development-stage biotech company: heavy dependence on external financing,...

high

Additional financing requirement

Development programs consume cash before any product revenue exists, so funding access is critical.

Scope
Company-wide development operations
Materiality
high
high

Clinical development uncertainty

Preclinical and clinical programs can fail on safety, efficacy, or pharmacokinetics.

Scope
NPM-115, NPM-119, NPM-139
Materiality
high
high

Regulatory delay or hold

FDA or other regulators can pause, narrow, or delay studies and commercialization.

Scope
Clinical-stage implant programs
Materiality
high
medium

Cortigent spin-off execution

The separation requires SEC, Nasdaq, tax, and board approvals and could be delayed or fail.

Scope
Cortigent neuromodulation business
Materiality
medium
medium

Third-party dependence

CROs, manufacturers, and study sites affect trial quality, timing, and cost.

Scope
Clinical and preclinical operations
Materiality
medium
Research and development expense
Clinical progress changes quarterly expense levels
Stock-based compensation
Can materially affect G&A and R&D expense
Grant accounting
Offsets development spend and affects comparability
Consolidation and spin-off accounting
Spin-off timing can change reported structure and balances

Integer Holdings Corp

ITGR · Electromedical & Electrotherapeutic Apparatus

Axogen, Inc.

AXGN · Electromedical & Electrotherapeutic Apparatus

CONMED Corp

CNMD · Electromedical & Electrotherapeutic Apparatus

InMode Ltd.

INMD · Electromedical & Electrotherapeutic Apparatus

LivaNova PLC

LIVN · Electromedical & Electrotherapeutic Apparatus

Electromed, Inc.

ELMD · Electromedical & Electrotherapeutic Apparatus

: 29/04/2026